New nanotech to detect cancer early | Joshua Smith

Episode Summary

Executive Summary: Joshua Smith argues that cancer outcomes depend heavily on early detection, but current screening is invasive, slow, costly, or unavailable for many cancers. He presents nano-DLD, an automated nanoscale separation technology designed to isolate exosomes from fluids like urine, blood, and saliva, enabling rapid liquid-biopsy screening that could make early cancer diagnosis more accessible and life-saving.

Main Topics: Why early cancer detection matters (Priority: 5/5): Smith frames cancer as widespread, emotionally devastating, and financially harmful, emphasizing that catching it early dramatically improves survival and reduces treatment burden. Limits of current screening methods (Priority: 5/5): He explains that many diagnostics are invasive, expensive, slow, or inaccurate, and that some cancers still lack effective screening tools altogether. Personal motivation and family experience (Priority: 4/5): Smith shares that his wife’s breast cancer diagnosis made the issue deeply personal and reinforced the value of routine screening and early intervention. Exosomes as biomarkers for liquid biopsy (Priority: 5/5): He describes exosomes as tiny vesicles shed by cells that carry molecular information, making them promising early-warning signals for cancer detection. nano-DLD technology for automated isolation (Priority: 5/5): Smith introduces nano-DLD, a chip-based deterministic lateral displacement system scaled to the nanoscale to automatically separate exosomes from other particles. Future of accessible, rapid diagnostics (Priority: 4/5): He envisions near-term screening from urine, blood, or saliva samples that could deliver results in minutes and eventually support home-based early warning systems.

Key Arguments: Early detection is the most important factor in improving cancer survival and reducing emotional and financial harm. Current cancer diagnostics are often too invasive, slow, costly, or unavailable to support frequent screening. Exosomes are ideal biomarkers because they are abundant in bodily fluids and reflect the molecular state of their cells of origin. The main barrier to exosome-based screening is the lack of an automated, economically accessible isolation method. nano-DLD adapts deterministic lateral displacement to the nanoscale, enabling continuous-flow separation of exosomes from other particles. Automation is essential to making regular cancer screening broadly accessible, potentially even in routine checkups or home settings.

Data Points: Lifetime cancer incidence: About 40% - Smith says roughly 40% of people will hear a cancer diagnosis in their lifetime. Cancer mortality among those diagnosed: Half will not survive - He states that about half of those diagnosed will die. Breast cancer stage 1 five-year survival: Nearly 100% - Used to illustrate the power of early diagnosis. Breast cancer stage 4 five-year survival: 22% - Used to contrast late-stage outcomes with early-stage outcomes. Cancer survivors going into debt: Roughly one-third - He notes the financial burden of treatment in the U.S. Bankruptcy risk: At least 2.5 times more likely - Cancer survivors are said to be more likely to declare bankruptcy than those without cancer. Exosome size: 30 to 150 nanometers - He defines exosomes as extremely small vesicles used as biomarkers. Exosomes per red blood cell: About 1 million - He compares exosome scale to the capacity of a red blood cell. Current gold-standard isolation time: About 30 hours - Ultracentrifugation is described as slow and labor-intensive. Current exosome diagnostics market timing: Just this year - He says the first exosome-based diagnostics emerged on the market recently. Near-term availability: Within the next few years - He suggests fluid-based screening could become practical soon. Longer-term availability: Within the next decade - He predicts the technology could be broadly available in that timeframe.

Pivotal Quotes: "You have cancer." — Joshua Smith: Opening line to underscore the emotional impact and prevalence of cancer. "Automation is the key to accessibility." — Joshua Smith: Central claim explaining why scalable screening technologies matter. "This would allow every man, woman, and child the opportunity to be regularly tested while they're still healthy, catching cancer when it first emerges." — Joshua Smith: Vision for widespread preventive screening enabled by his technology.

Implications: If successful, nano-DLD could make early cancer screening faster, cheaper, and less invasive, improving survival and reducing financial strain. It could also expand liquid biopsy into routine care and eventually home-based monitoring.